Clinical Trial Update: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects [Phase 1]

View source ↗

Summary

This Phase 1 first-in-human study of an anti-IL-20 therapy for psoriasis evaluated safety and tolerability with early biological and clinical signals; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Anti-IL-20 (anti-IL-20 antibody)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Psoriasis | Phase 1 | Status: TERMINATED